Gilead Sciences Inc.
Lenacapavir medicine bottle
WHO recommended the use of the drug Lenacapavir, an antiretroviral of prolonged action, to prevent HIV/AIDS infection.
The World Health Organization (WHO) recommended This week the use of the medicine Lenacapavir, an antiretroviral of prolonged action, to prevent the infection by ViH / like.
According to WHO, it is a historical decision that “can help Reformulate the global response to HIV“.
In, WHO, which published new guidelines, says that the drug Lenacapavir “offers a highly effective and prolonged action alternative To the daily oral tablets and other shorter action options ”if it is administered as injectable every six months.
With only Two doses per year“It represents a transformative step in the protection of people at risk” of infection by AIDS virus, particularly those that “face challenges with daily adhesion, stigma or access to health care,” the UN organization adds.
Although there is no vaccine against HIV/AIDS, the Drug Lenacapavir “It’s the second best thing”according to WHO Director General, Tedros Adhanom Ghebreyesus.
“An antiretroviral of prolonged action that demonstrated in essays to prevent almost all VIH infections among people at risk,” he said, cited in the statement, highlighting WHO’s commitment to “working with countries and partners to ensure that this innovation reaches communities as quickly and safely as possible.”
According to WHO, the new guidelines arise in a “Critical moment”, since “the prevention efforts”Of HIV/AIDS infection“ are stagnant ”, with 1.3 million new cases recorded in 2024.
A WHO estimates that, not the end of 2024, Havia no world 40.8 million people with HIV/AIDS65% lived in Africa. That year, about 630 thousand people died in the world of causes related to infection.
The United Nations Program for HIV/AIDS (onusida) warned last week that the United States financing cuts For prevention and treatment, up to 2030 six million new infections and four million deaths may occur.
In the European Union, the drug Lenacapavir is used, along with other drugs, to treat adult With HIV-1, being administered when the virus is resistant to other treatments.
The drug, marketed with the name of Sunlenca, It is available in tablets and in injectable solution.
The United States approved in June the use of the drug as a semiannual injectable for the prevention of HIV/AIDS infection, under the Yeztugo brand.
